¡á ƯÇã¸íĪ : ½Ã½ºÅ×ÀÎ Àܱ⸦ Æ÷ÇÔÇÏ´Â ¸ðƼÇÁ°¡ °áÇÕµÈ º¯ÇüÇ×ü, »ó±â º¯ÇüÇ×ü¸¦ Æ÷ÇÔÇÏ´Â º¯ÇüÇ×ü-¾à¹° Á¢ÇÕü ¹× ±× Á¦Á¶¹æ¹ý(ÀϺ» ƯÇã)
MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION
¡á ƯÇã ÁÖ¿ä³»¿ë : º» ƯÇã´Â Â÷¼¼´ë Ç×¾Ï Ç×üÀǾàÇ° ±â¼ú Ç×ü-¾à¹° Á¢ÇÕ ±â¼ú(ADC, Antibody-Drug Conjugate)°ú °ü·ÃµÈ ƯÇã·Î¼, Ç×ü¿¡ ¾à¹°ÀÌ ½±°Ô À§Ä¡¼±ÅÃÀû(Site-specific)À¸·Î Á¢ÇÕÇϵµ·Ï Ç×ü¸¦ º¯Çü½ÃÅ°´Â ±â¼úÀÓ
¡á ƯÇã±ÇÀÚ : ÁÖ½Äȸ»ç ¾ËÅ׿ÀÁ¨
¡á ƯÇãÃëµæÀÏÀÚ : 2016-12-21
¡á ƯÇã È°¿ë°èȹ
- Ç×ü-¾à¹° Á¢ÇÕ(ADC) ±â¼úÀº Ç×¾ÏÈ¿°ú°¡ ¶Ù¾î³ Ç׾Ͼ๰À» Ÿ°Ù Ä¡·áÁ¦ÀÎ Ç×üÀǾàÇ°°ú Á¢ÇÕÇÏ¿© °·ÂÇÑ È¿´ÉÀÇ Ç׾Ͼ๰ÀÌ ¾Ï¼¼Æ÷¿¡¸¸ ÀÛ¿ëÇϵµ·Ï ÇÏ´Â ±â¼úÀÓ
- º» ±â¼úÀº Ç×üÀǾàÇ°°ú ¾à¹°ÀÇ Á¢ÇÕ À§Ä¡ ¹× Á¢ÇÕ °¹¼ö¸¦ Á¶ÀýÇÒ ¼ö ÀÖ´Â Ç×ü-¾à¹° Á¢ÇÕ ±â¼ú·Î¼ ±âÁ¸ÀÇ Ç×ü-¾à¹° Á¢ÇÕ ±â¼úº¸´Ù °³¼±µÈ 2¼¼´ë ±â¼úÀÓ
- ÇöÀç º» ±â¼úÀ» Àû¿ëÇÏ¿© ADC À¯¹æ¾Ï/À§¾ÏÄ¡·áÁ¦¿Í ADC ³¼Ò¾ÏÄ¡·áÁ¦¸¦ °³¹ß ÁßÀ̸ç, ADC À¯¹æ¾Ï/À§¾ÏÄ¡·áÁ¦´Â ÀüÀÓ»ó½ÃÇèÀ» ¸¶Ä¡°í ÀÓ»ó1»óÀ» À§ÇÑ ÀÓ»ó°èȹ¼¸¦ Á¦ÃâÇÑ »óÅÂÀÓ
¡á È®ÀÎÀÏÀÚ : 2016-12-23
¡á ±âŸ ÅõÀÚÆÇ´Ü¿¡ Âü°íÇÒ »çÇ×
- ƯÇãµî·Ï±¹°¡ : ÀϺ»
- »ó±â ƯÇã´Â ÀϺ» ÀÌ¿Ü¿¡µµ Çѱ¹, È£ÁÖ, ·¯½Ã¾Æ¿¡¼ µî·ÏÀÌ ¿Ï·áµÇ¾úÀ¸¸ç, ¹Ì±¹, À¯·´, Áß±¹ µî¿¡ Ãâ¿øÀÌ µÈ »óÅÂÀÓ
Á¶º´¿í ±âÀÚ bucho85@pharmstock.co.kr
<ÀúÀÛ±ÇÀÚ © ÆʽºÅ¹, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>